ABL Inc., a biomedical contractor based in Rockville, is working to advance the development of a new vaccine platform.
The company is working with Najit Technologies Inc., an Oregon biotech company, on Najit’s HydroVax plaform, which is designed to optimize the provoking of an immune response through the use of inactivated viruses.
ABL will provide process development, production of virus seeds, bulk drug substance and aseptic fill and finish. Vaccines are in development for Chikungunya, Zika, Dengue and yellow fever virus infections.
The Maryland company’s work has the potential to establish a platform process for Najit’s technology, which could speed development of vaccines.